12:00 AM
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TZP-102: Phase IIb discontinued

Tranzyme discontinued the double-blind, U.S. and Polish Phase IIb DIGEST trial in patients with Type I or II diabetes and a history of symptoms of gastroparesis after a planned interim futility analysis examining patient responsiveness to thrice-daily 10 mg TZP-102 or placebo given before meals for 12 weeks showed insufficient efficacy at the end of weeks 4 and...

Read the full 269 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >